Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Cancer Lett. 2015 Sep 1;369(1):229–241. doi: 10.1016/j.canlet.2015.08.021

Figure 8.

Figure 8

MDA-MB-231-luc breast tumor response to OXi8007 treatment assessed by BLI. Sequential images of representative SCID mice bearing orthotopic MDA-MB-231-luc breast tumors growing in the mammary fat pad were obtained following administration of (A) OXi8007 (350 mg/kg) and (C) saline vehicle. Signals were obtained at 2, 6, and 24 h after treatment and 15 minutes after fresh luciferin substrate injection. (B) Representative dynamic BLI showing signal intensity evolution over 35 minutes for an MDA-MB-231-luc tumor from a mouse treated with OXi8007 (350 mg/kg). (D) Bar plot for normalized mean maximum BLI signal ± S.D. of tumors from cohorts of mice (n = 5) at different time-points post drug administration. OXi8007 and CA4P induced significant reduction in BLI of tumors (***p < 0.001, *p < 0.05). OXi8007 BLI signal remained low at 24 h whereas CA4P showed significant recovery between 6 and 24 h post treatment (*p < 0.05).